Bioveika - Company finances
|
EUR
|
2019
From: 2019-01-28
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 52,708 | 269,969 | 174,172 | 9,232 | 1,458,938 | 244,705 | 6,000 |
| Profit before tax | - | - | - | - | - | - | - |
| Net profit | 15,971 | 15,139 | 35,792 | 672 | 76,704 | -6,826 | -413 |
| Equity | 18,971 | 24,110 | 59,902 | 60,574 | 122,279 | 65,453 | 65,040 |
| Liabilities | 67,621 | 210,690 | 119,634 | 58,878 | 151,533 | 15,372 | 13,250 |
| Non-current assets | 0 | 18,083 | 70,885 | 68,939 | 5,687 | 3,555 | 1,423 |
| Current assets | 86,592 | 216,412 | 108,651 | 49,656 | 267,927 | 77,270 | 76,867 |
| Total assets | 86,592 | 234,495 | 179,536 | 118,595 | 273,614 | 80,825 | 78,290 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 20,767 | 29,944 | 1,969 |
| Social insurance contributions | - | - | - | - | 237 | 139 | - |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +412.2% | -35.5% | -94.7% | +15703.1% | -83.2% | -97.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 18.4% | 6.5% | 19.9% | 0.6% | 28.0% | -8.4% | -0.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 84.2% | 62.8% | 59.8% | 1.1% | 62.7% | -10.4% | -0.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 30.3% | 5.6% | 20.5% | 7.3% | 5.3% | -2.8% | -6.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 3.6 | 8.7 | 2.0 | 1.0 | 1.2 | 0.2 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 26,354 | 85,252 | 56,489 | 4,103 | 486,313 | 79,365 | 2,000 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Bioveika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-12-18 | 2023-12-26 | 85.04 |
| 2023-11-16 | 2023-12-17 | 0.59 |
| 2023-10-27 | 2023-11-02 | 0.59 |
| 2023-10-25 | 2023-10-25 | 0.59 |
| 2023-08-17 | 2023-08-28 | 156.21 |
Bioveika - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-10-01 | 2024-10-09 | 104.42 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Bioveika, UAB (code 304998930) is a Private Limited Liability Company engaged in the construction of utility projects for electricity and telecommunications. The company’s financial profile weakened markedly by 2025. Revenue declined from €1.46M in 2023 to €244.7K in 2024 and then to just €6.0K in 2025. Net profit followed the same direction, moving from €76.7K in 2023 to a loss of €6.8K in 2024 and a small loss of €413 in 2025. The 2025 profit margin was -6.9%, reflecting limited operating volume and continued pressure on earnings. The balance sheet remained small, with total assets of €78.3K, equity of €65.0K and liabilities of €13.2K at the end of 2025. The equity ratio was 83.1% and debt-to-equity stood at 0.20, indicating low leverage. Asset turnover was 0.08x, while ROE and ROA were both slightly negative at -0.6% and -0.5%. Revenue per employee was €2.0K, with profit per employee at -€138.